Lingling Wang Jiao Tang Jun Feng Yongfen Huang Yuexin Cheng Hao Xu Yuqing Miao
10.3389/fimmu.2022.1001482
Front Immunol
2022 Oct 17;13:1001482.
b cell igm kmt2d mecom myd88 waldenstrom macroglobulinemia acute lymphoblastic leukemia plasma cells
CC BY
https://pubmed.ncbi.nlm.nih.gov/36325357/
Burkitt Lymphoma Lymphoma, B-Cell Precursor Cell Lymphoblastic Leukemia-Lymphoma Waldenstrom Macroglobulinemia / complications Waldenstrom Macroglobulinemia / diagnosis Waldenstrom Macroglobulinemia / drug therapy
Burkitt Lymphoma Lymphoma, B-Cell Precursor Cell Lymphoblastic Leukemia-Lymphoma Waldenstrom Macroglobulinemia / complications Waldenstrom Macroglobulinemia / diagnosis Waldenstrom Macroglobulinemia / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Dexamethasone / therapeutic use Female Humans MDS1 and EVI1 Complex Locus Protein / genetics MDS1 and EVI1 Complex Locus Protein / therapeutic use Mutation Myeloid Differentiation Factor 88 / genetics Tumor Microenvironment Myeloid Differentiation Factor 88 Dexamethasone MECOM protein, human MDS1 and EVI1 Complex Locus Protein
PMC9618799
36325357
Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations
2022